Patient Centricity

The Evolution of Patient Centricity in Pharma (Pre-2020 to 2025): From Aspiration to Embedded Reality

Patient centricity: A defining imperative in healthcare As patient expectations evolve and regulatory bodies demand greater transparency, the pharmaceutical industry is undergoing a profound transformation in terms of patient centricity. Our latest white paper, “The Evolution of Patient Centricity in Pharma (Pre-2020 to 2025): From Aspiration to Embedded Reality,” explores how patient centricity has shifted from…...
Read More

Top Stories

Nelson memo

The Nelson Memo: Igniting a Global Open Data

The landscape of scientific research is undergoing a seismic...
Rare diseases

Rare Diseases – An Evolving Medical

A disease is considered rare when it affects fewer than 1 in...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
ISMPP

21st Annual Meeting of ISMPP: A Summarized Report

The 21st Annual Meeting of ISMPP was held from May 12-14, 2025, in Washington, D.C...
MAPS EMEA 2025

Amplifying the Patient Voice: Reflections from MAPS EMEA 2025

At this year’s MAPS EMEA 2025 Annual Meeting in London, the message was clear: the...
Graphical or Visual Abstracts

Graphical Abstracts – Communicating Complex Information Visually

Three years ago, we explored how visual abstracts revolutionize research communication by transforming dense scientific findings into...
MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook for Successful Drug Launches

At the MAPS Americas 2025 conference in New Orleans, one of the pivotal discussions centered...
DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical...
Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks like it may be particularly challenging...

Learn more ABOUT our company.